Zanosar (Intravenous)
Zanosar (Intravenous) Uses, Dosage, Side Effects, Food Interaction and all others data.
An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.
Zanosar (Intravenous) is an antitumour antibiotic consisting of a nitrosourea moiety interposed between a methyl group and a glucosamine. Zanosar (Intravenous) is indicated in the treatment of metastatic islet cell carcinoma of the pancreas. Zanosar (Intravenous) inhibits DNA synthesis in bacterial and mammalian cells. In bacterial cells, a specific interaction with cytosine moieties leads to degradation of DNA. The biochemical mechanism leading to mammalian cell death has not been definitely established; streptozocin inhibits cell proliferation at a considerably lower level than that needed to inhibit precursor incorporation into DNA or to inhibit several of the enzymes involved in DNA synthesis. Although streptozocin inhibits the progression of cells into mitosis, no specific phase of the cell cycle is particularly sensitive to its lethal effects.
Trade Name | Zanosar (Intravenous) |
Availability | Prescription only |
Generic | Streptozocin |
Streptozocin Other Names | Estreptozocina, Streptozocin, Streptozocine, Streptozocinium, Streptozocinum, Streptozotocin |
Related Drugs | fluorouracil, gemcitabine, everolimus, Lynparza, Abraxane, Afinitor |
Type | |
Formula | C8H15N3O7 |
Weight | Average: 265.2206 Monoisotopic: 265.090999849 |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | USA |
Last Updated: | September 19, 2023 at 7:00 am |
![Zanosar (Intravenous) Zanosar (Intravenous)](https://www.medicinesfaq.com/media/png/zanosar-intravenous.png)
Uses
Zanosar (Intravenous) is a nitrosourea antineoplastic agent used in the treatment of metastatic pancreatic islet cell carcinoma.
For the treatment of malignant neoplasms of pancreas (metastatic islet cell carcinoma).
Zanosar (Intravenous) is also used to associated treatment for these conditions: Stage 4 islet cell carcinoma
How Zanosar (Intravenous) works
Although its mechanism of action is not completely clear, streptozocin is known to inhibit DNA synthesis, interfere with biochemical reactions of NAD and NADH, and inhibit some enzymes involved in gluconeogenesis. Its activity appears to occur as a result of formation of methylcarbonium ions, which alkylate or bind with many intracellular molecular structures including nucleic acids. Its cytotoxic action is probably due to cross-linking of strands of DNA, resulting in inhibition of DNA synthesis.
Toxicity
Symptoms of overdose include nausea and vomiting, anorexia, myelosuppression; and nephrotoxicity.
Food Interaction
No interactions found.Zanosar (Intravenous) Disease Interaction
Major: hepatic dysfunction, myelosuppression, renal dysfunctionModerate: diabetes
Elimination Route
Poor oral absorption (17-25%)
Half Life
5-15 minutes
Elimination Route
As much as 20% of the drug (or metabolites containing an N-nitrosourea group) is metabolized and/or excreted by the kidney.
Innovators Monograph
You find simplified version here Zanosar (Intravenous)